sharon sanders
Editor-in-Chief & President
So 80% are infected with other....what?......
Zhong Nanshan: More than 20% of patients tested in Guangzhou fever clinic are infected with new coronavirus
17:01, May 15, 2023 CCTV
19
On the afternoon of May 15, at the launching ceremony of the post-launch clinical research of Laritevir, Zhong Nanshan, a medalist of the Republic and an academician of the Chinese Academy of Engineering, said that the mainstream new coronavirus strain currently prevalent in Guangzhou is XBB1.9.1. According to the current data of fever clinics in Guangzhou, 20%-25% of the fever patients tested are infected with the new coronavirus.
Zhong Nanshan introduced that whether there are symptoms or no symptoms, if the antibody corresponding to the new coronavirus in the body increases, it means that the human body has been infected. From this perspective, according to the measurement, about 85% of the people in the country have been infected with the new crown virus, about 1.1 billion to 1.2 billion people. According to relevant laboratory studies and real-world studies in Singapore and other places, the antibodies produced after infection with the new coronavirus can protect the human body within 4-6 months; but if faced with the mutant strain XBB, its protection may be It will weaken. "From December last year, it actually looks like this time has come."
Zhong Nanshan revealed that in the next step to deal with the new coronavirus infection, on the one hand, it is necessary to develop vaccines that can cover XBB mutant strains, including mRNA vaccines and recombinant protein vaccines. These vaccines are mainly aimed at some special groups, such as those with low immunity or other serious conditions. On the other hand, once infected with the new crown, timely drug treatment should be given, which can greatly reduce the mortality rate.
It is understood that Laritevir is my country's first single-drug 3CL anti-new crown class 1 innovative drug. It has been approved for marketing in March with conditions for the treatment of adult patients with mild to moderate symptoms of new crown. Studies have shown that the antiviral effect of the drug is comparable to that of Pfizer Paxlovid has the same effect and effectively avoids the toxic side effects caused by the combination with ritonavir.
source: zhttps://news.sina.com.cn/c/2023-05-15/doc-imytwhku0469682.shtml?cre=tianyi&mod=pcpager_socie ty&loc=18&r=0&rfunc=96&tj=cxvertical_pc_pager_spt& tr=174#/
Zhong Nanshan: More than 20% of patients tested in Guangzhou fever clinic are infected with new coronavirus
17:01, May 15, 2023 CCTV
19
On the afternoon of May 15, at the launching ceremony of the post-launch clinical research of Laritevir, Zhong Nanshan, a medalist of the Republic and an academician of the Chinese Academy of Engineering, said that the mainstream new coronavirus strain currently prevalent in Guangzhou is XBB1.9.1. According to the current data of fever clinics in Guangzhou, 20%-25% of the fever patients tested are infected with the new coronavirus.
Zhong Nanshan introduced that whether there are symptoms or no symptoms, if the antibody corresponding to the new coronavirus in the body increases, it means that the human body has been infected. From this perspective, according to the measurement, about 85% of the people in the country have been infected with the new crown virus, about 1.1 billion to 1.2 billion people. According to relevant laboratory studies and real-world studies in Singapore and other places, the antibodies produced after infection with the new coronavirus can protect the human body within 4-6 months; but if faced with the mutant strain XBB, its protection may be It will weaken. "From December last year, it actually looks like this time has come."
Zhong Nanshan revealed that in the next step to deal with the new coronavirus infection, on the one hand, it is necessary to develop vaccines that can cover XBB mutant strains, including mRNA vaccines and recombinant protein vaccines. These vaccines are mainly aimed at some special groups, such as those with low immunity or other serious conditions. On the other hand, once infected with the new crown, timely drug treatment should be given, which can greatly reduce the mortality rate.
It is understood that Laritevir is my country's first single-drug 3CL anti-new crown class 1 innovative drug. It has been approved for marketing in March with conditions for the treatment of adult patients with mild to moderate symptoms of new crown. Studies have shown that the antiviral effect of the drug is comparable to that of Pfizer Paxlovid has the same effect and effectively avoids the toxic side effects caused by the combination with ritonavir.
source: zhttps://news.sina.com.cn/c/2023-05-15/doc-imytwhku0469682.shtml?cre=tianyi&mod=pcpager_socie ty&loc=18&r=0&rfunc=96&tj=cxvertical_pc_pager_spt& tr=174#/